



2022 the name of our Company was changed to 'Sagility India Private Limited' and a fresh certificate of incorporation was issued by the Registrar of Companies, Karnataka at Bengaluru on September 13, 2022. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by our Shareholders at the EGM held on May 21, 2024 and the name of our Company was changed to 'Sagility India Limited', and a fresh certificate of incorporation was issued to our Company by the RoC, on June 20, 2024. For details of changes in the name and registered office address of our Company, see 'History and Certain Corporate Matters' on page 194 of the ospectus dated November 7, 2024 ("Prospectus")

Registered Office: No. 23 & 24, AMR Tech Park, Building 2A, First Floor, Hongasandara Village, Off Hosur Road, Bommanahalli, Bengaluru 560068, Karnataka, India; Corporate Office: AMR Tech Park, Building 2A, Third Floor, Hongasandara Village, Off Hosur Road, Bommanahalli, Bengaluru 560068, Karnataka, India; Corporate Office: AMR Tech Park, Building 2A, Third Floor, Hongasandara Village, Off Hosur Road, Bommanahalli, Bengaluru 560068, Karnataka, India; Tel: +91- 80-7125 1500; Contact Person: SatishKumar Sakharayapattana Seetharamaiah, Company Secretary and Compliance Officer; E-mail: investorservice@sagilityhealth.com; Corporate Identity Number: U72900KA2021PLC150054

OUR PROMOTERS: SAGILITY B.V. AND SAGILITY HOLDINGS B.V.

ANCHOR INVESTOR OFFER PRICE: ₹ 30 PER EQUITY SHARE OF FACE VALUE OF ₹ 10 EACH OFFER PRICE: ₹ 30 PER EQUITY SHARE OF FACE VALUE OF ₹ 10 EACH THE OFFER PRICE IS 3.00 TIMES OF THE FACE VALUE OF THE EQUITY SHARES

RISKS TO INVESTORS:

For details, refer to "Risk Factors" on page 40 of the Prospectus.

- competitive and if we are unable to compete effectively, it may adversely affect our business, financial condition and results of operations. Within the healthcare operations outsourcing market, we had a share of approximately 1.18% and approximately 1.23% in 2022 and 2023 respectively (Source: Everest Report).
- 2. Industry Risk: Our business is solely focused on the U.S. healthcare industry and may be adversely affected by factors affecting the U.S. healthcare industry, including a decline in the growth of the U.S. healthcare industry, reduction in outsourcing and other trends.
- 3. Risk relating to the price of our Equity Shares: We have, in the 12 months preceding the date of the Red Herring Prospectus, issued Equity Shares at a price which may be significantly lower than the Offer Price, including an allotment on May 31, 2024, at a price of ₹28.30 per share.
- 4. Impairment Risk: Goodwill and other intangible assets are our largest assets. Any impairment to our goodwill or other intangible assets may adversely affect our reputation and financial condition. As of June 30, 2024, our goodwill and intangible assets amounted ₹56,792.60 million and ₹19,669.87 million, respectively, representing 54.67% and 18.94% of our total assets.
- 5. Regulatory Action Risk: Dr. Shalini Sarin, one of our Independent Directors, has received summons, under the Securities and Exchange Board of India Act, 1992 seeking co-operation and certain information in relation to an ongoing investigation involving Linde India Limited.
- 6. Promoters' Credit Risks: Pursuant to an external financing facility availed by one of our Promoters, Sagility B.V., shares of Sagility B.V. held by our other Promoter, Sagility Holdings B.V. are pledged. In case of an event of default and consequent invocation of security, there may be a change in control, which may adversely impact our business.
- 7. Risks relating to regulatory changes: Anti-outsourcing legislation could adversely affect our business, financial condition and results of operations and impair our ability to service our customers.
- 8. Risk relating to our credit rating: Our Company received a BBB (Stable)/A3+ credit rating from ICRA Limited on October 9, 2024. A downgrade in our credit rating could adversely affect our ability to raise capital in the future.
- 9. IP infringement risk: Any failure to protect our proprietary technologies or information or our intellectual property rights may have an adverse effect on our business, financial condition, and results of operations.
- 10. Risks relating to limits on foreign investment: Under Indian foreign investment laws, an Indian company is permitted to invest in overseas joint ventures or subsidiaries, up to 400% of the Indian company's net worth as at the date of its last audited balance sheet. Our ability to invest in foreign subsidiaries or joint ventures is constrained by such regulations as well as other laws.

- 1. Competition Risk: The healthcare services industry is highly 11. OFS related risk: The proceeds from this Offer for Sale will be paid to the Promoter Selling Shareholder (after deducting applicable Offer related expenses and relevant taxes thereon) and our Company will not receive any such proceeds
 - 12. Weighted average Return on Net Worth for the Financial Years 2024, 2023 and For the period beginning from July 28, 2021 to March 31, 2022 is 2.52%.
 - 13. Details of weighted average cost of acquisition of all Equity Shares transacted in the last three years, 18 months and one year preceding the date of the Prospectus:

Period	Weighted	Lower	Upper	Range of
	average	End of	End of	acquisition
	cost of	the Price	the Price	price
	acquisition	Band is 'X'	Band is 'X'	Lowest Price
	(WACA)	times the	times the	- Highest Price
	(in ₹)*	WACA	WACA	(in ₹)*
Last three years	20.79	1.35	1.44	10.00-30.00
Last 18 months	28.65	0.98	1.05	28.30-30.00
Last one year	28.65	0.98	1.05	28.30-30.00
* As sortified by	· Agamual I	oin O Cum	to Charters	d Assertante

- As certified by Agarwal Jain & Gupta, Chartered Accountants, pursuant to their certificate dated November 7, 2024.
- 14. Weighted average cost of acquisition ("WACA"), floor price and cap price

Past Transactions	Weighted average	Floor	Cap
	cost of acquisition	Price	Price
	(in ₹) [#]	(in ₹)	(in ₹)
WACA of equity shares that	28.30	0.99	1.06
were issued by our Company		times	times
WACA of equity shares that	28.65	0.98	1.05
were acquired or sold by way		times	times
of secondary transactions			

*As certified by Agarwal Jain & Gupta, by way of their certificate dated November 7, 2024

15. The book running lead managers ("BRLMs") have handled 81 public offers in the past three Financial Years, out of which 19 offers have closed below the offer price on the listing date

Name of BRLM	Total Public Issues	Issues closed below Offer Price
ICICI Securities Limited	32	6
IIFL Securities Limited	20	5
Jefferies India Private Limited	3	0
J. P. Morgan India Private Limited	4	1
Common Issues by BRLMs	22	7
Total	81	19

BID/ OFFER PROGRAMME

ANCHOR INVESTOR BIDDING DATE OPENED AND CLOSED ON: MONDAY, NOVEMBER 4, 2024 BID/OFFER OPENED ON: TUESDAY, NOVEMBER 5, 2024 | BID/OFFER CLOSED ON: THURSDAY, NOVEMBER 7, 2024

The Offer was made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(2) of the SEBI ICDR Regulations, wherein not less than 75% of the Net Offer was allocated on a proportionate basis to the Qualified Institutional Buyers ("QIBs") ("QIB Portion"), provided that our Company in consultation with the BRLMs, made available for allocation up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which at least one-third was reserved for domestic Mutual Funds at or above the Anchor Investor Portion"), of which at least one-third was reserved for domestic Mutual Funds at or above the Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion was made available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion was available for allocation on a proportionate basis to Non-Institutional Investors of which (a) one-third of such portion was reserved for applicants with application size of more than ₹1.00 million; and (b) two-third of such portion was reserved for applicants with application size of more than ₹0.20 million; and (b) two-third of such portion was reserved for applicants with application size of more than ₹1.00 million, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders and not more than 10% of the Net Offer was available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids received at or above the Offer Price. All potential Bidders (except Anchor Investors) were required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and U

Funds through 26 Mutual Fund schemes) for 33,17,83,500 Equity Shares. The Anchor Investor Offer Price was finalized at \leq 30 per Equity Share. A total of 31,51,34,668 Equity Shares were allocated under the Anchor Investor Portion aggregating to \leq 9,45,40,40,040.

The Offer received 4,84,095 applications for 1,57,56,56,000 Equity Shares (prior to rejections) resulting in 2.24 times subscription as disclosed in the Prospectus. The details of the applications received in the Offer from various categories are as under (hefore rejections):

SR. NO.	CATEGORY	NO. OF APPLICATIONS RECEIVED	NO. OF EQUITY SHARES APPLIED	NO. OF EQUITY SHARES AVAILABLE FOR ALLOCATION AS PER PROSPECTUS	NO. OF TIMES SUBSCRIBED	AMOUNT (₹)
A	Retail Individual Bidders	4,60,251	29,51,76,000	7,00,29,926	4.21	8,85,11,07,000
В	Non-Institutional Bidders – More than ₹ 0.20 million and up to ₹ 1.00 million	11,334	8,48,11,500	3,50,14,963	2.42	2,54,28,92,000
С	Non-Institutional Bidders – Above ₹ 1.00 million	2,399	11,85,88,000	7,00,29,926	1.69	3,55,67,80,000
D	Eligible Employees	10,024	70,62,500	19,00,000	3.72	19,75,73,000
Е	Qualified Institutional Bidders (excluding Anchor Investors)	35	73,82,34,500	21,00,89,779	3.51	22,14,70,35,000
F	Anchor Investors	52	33,17,83,500	3,15,134,668	1.05	9,95,35,05,000
	Total	4,84,095	1,57,56,56,000	70,21,99,262	2.24	47,24,88,92,000

Final Demand

A summary of the final demand as per BSE and NSE as on the Bid/Offer Closing Date and as at different Bid prices is as under:

Sr. No	Bid Price (₹)	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1	28	94,03,500	0.66	94,03,500	0.66
2	29	30,18,000	0.21	1,24,21,500	0.87
3	30	1,01,09,07,000	70.81	1,02,33,28,500	71.68
4	CUT-OFF	40,42,22,500	28.32	1,42,75,51,000	100.00
	TOTAL	1,42,75,51,000	100.00		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being the NSE, on Friday, November 8, 2024.

A. Allotment to Retail Individual Bidders (after rejections) (including ASBA Applications)

The Basis of Allotment to the Retail Individual Bidders, who have bid at the Cut-Off Price or at the Offer Price of ₹30 per Equity Share, was finalized in consultation with the NSE. This category has been subscribed to the extent of 3.98 times (including spillover from Eligible Employee category). The total number of Equity Shares Allotted in the Retail Portion is 7,01,23,176 Equity Shares (including spillover of 93,250 Equity Shares from Eligible Employee category) to 1,40,246 successful Retail Individual Bidders. The category-wise details of the Rasis of Allotment are as under:

Sr. No			Total No. of Equity % to Total Shares applied		No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted	
1	500	3,87,604	89.04	19,38,02,000	69.46	500	48:149	6,24,35,000
2	1,000	27,801	6.39	2,78,01,000	9.96	500	48:149	44,78,000
3	1,500	7,055	1.62	1,05,82,500	3.79	500	48:149	11,36,500
4	2,000	3,818	0.88	76,36,000	2.74	500	48:149	6,15,000
5	2,500	2,060	0.47	51,50,000	1.85	500	48:149	3,32,000
6	3,000	1,527	0.35	45,81,000	1.64	500	48:149	2,46,000
7	3,500	985	0.23	34,47,500	1.24	500	48:149	1,58,500
8	4,000	377	0.09	15,08,000	0.54	500	48:149	61,000
9	4,500	195	0.04	8,77,500	0.31	500	63:195	31,500
10	5,000	1,044	0.24	52,20,000	1.87	500	48:149	1,68,000
11	5,500	100	0.02	5,50,000	0.20	500	32:100	16,000
12	6,000	228	0.05	13,68,000	0.49	500	73:228	36,500
13	3 6,500 2,538		0.58	1,64,97,000	5.91	500	48:149	4,09,000
		15,376 Allottees from S	Serial no 2 to 13 A	dditional 1 (one) share.		1	1:87	176
	TOTAL	4,35,332	100.00	27,90,20,500	100.00			7,01,23,176

B. Allotment to Non-Institutional Bidders (more than ₹ 0.20 million and up to ₹ 1.00 million) (after rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Bidders (more than ₹ 0.20 million and up to ₹ 1.00 million), who have bid at the Offer Price of ₹30 per Equity Share or above, was finalized in consultation with the NSE. This category has been subscribed to the extent of 2.34 times (including spillover from Eligible Employee category). The total number of Equity Shares Allotted in this category is 35,061,588 Equity Shares (including spillover 46,625 Equity Shares from Eligible Employee category) to 5,008 successful Non-Institutional Bidders (none than ₹ 0.20 million) and up to ₹ 1.00 million and up to ₹ 1.00 million. The extension-wise details of the Basis of Allotment are as under (Sample).

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares allotted per applicant	Ratio	Total No. of Equity Shares allotted
1	7,000	10,123	92.09	7,08,61,000	86.33	7,000	41:90	3,22,84,000
2	7,500	174	1.58	13,05,000	1.59	7,014	79:174	5,54,106
3	3 8,000 86 0.78		6,88,000	0.84	7,014	39:86	2,73,546	
4	8,500	21	0.19	1,78,500	0.22	7,014	10:21	70,140
5	9,000	40	0.36	3,60,000	0.44	7,014	18:40	1,26,252
6	9,500	8	0.07	76,000	0.09	7,014	4:8	28,056
7	10,000	139	1.26	13,90,000	1.69	7,014	63:139	4,41,882
8	10,500	6	0.05	63,000	0.08	7,014	3:6	21,042
9	11,000	9	0.08	99,000	0.12	7,014	4:9	28,056
10	11,500	4	0.04	46,000	0.06	7,014	2:4	14,028
20	16,500	124	1.13	20,46,000	2.49	7,014	56:124	3,92,784
21	17,000	22	0.20	3,74,000	0.46	7,014	10:22	70,140
22	17,500	7	0.06	1,22,500	0.15	7,014	3:7	21,042
23	18,000	6	0.05	1,08,000	0.13	7,014	3:6	21,042
24	20,000	21	0.19	4,20,000	0.51	7,014	10:21	70,140
25	21,000	7	0.06	1,47,000	0.18	7,014	3:7	21,042
26	22,000	3	0.03	66,000	0.08	7,014	1:3	7,014
27	23,500	2	0.02	47,000	0.06	7,014	1:2	7,014
28	24,000	2	0.02	48,000	0.06	7,014	1:2	7,014
29	25,000	13	0.12	3,25,000	0.40	7,014	6:13	42,084
30	26,500	2	0.02	53,000	0.06	7,014	1:2	7,014
501	18,500	1	0.01	18,500	0.02	7,014	0:1	0
502	19,000	1	0.01	19,000	0.02	7,014	0:1	0
503	22,500	1	0.01	22,500	0.03	7,014	0:1	0
504	25,500	1	0.01	25,500	0.03	7,014	0:1	0
505	28,500	1	0.01	28,500	0.03	7,014	0:1	0
506	30,500	1	0.01	30,500	0.04	7,014	0:1	0
507	31,000	1	0.01	31,000	0.04	7,014	0:1	0
		All applicants from	m Serial no 501 to	507 for 1 (one) lot of 7,0	14 shares	7,014	3:7	21,042
		396 Allottees	from Serial no 2 t	o 508 Additional 1(one) s	hare	1	1:9	44
	TOTAL	10,993	100.00	8,20,81,000	100.00			3,50,61,588

C. Allotment to Non-Institutional Bidders (more than ₹1.00 million) (after rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Bidders (more than ₹ 1.00 million), who have bid at the Offer Price of ₹30 per Equity Share or above, was finalized in consultation with the NSE. This category has been subscribed to the extent of 1.64 times (including spillover from Eligible Employee category). The total number of Equity Shares Allotted in this category is 7,01,23,176 Equity Shares (including spillover of 93,250 Equity Shares from Eligible Employee category) to 2,305 successful Non-Institutional Bidders (more than ₹ 1.00 million). The category-wise details of the Basis of Allotment are as under (Sample).

1.00	minorij. Trio oat	ogory woo dotallo or the E	aoio on monnonta	io do dildor. (odinipio)				
Sr.	Category	No. of Applications	% of Total	Total No. of Equity	% to Total	No. of Equity Shares	Ratio	Total No. of Equity
No		Received		Shares applied		allotted per applicant		Shares allotted
1	33,500	2,111	91.58	7,07,18,500	61.33	21,427	1:1	4,52,32,397
		1 additiona	al share for Catego	ory 33,500		1	37:93	840
2	34,000	24	1.04	8,16,000	0.71	21,700	1:1	5,20,800
3	34,500	2	0.09	69,000	0.06	21,972	1:1	43,944
4	35,000	50	2.17	17,50,000	1.52	22,244	1:1	11,12,200
5	35,500	1	0.04	35,500	0.03	22,516	1:1	22,516

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted
6	36,000	6	0.26	2,16,000	0.19	22,789	1:1	1,36,734
7	36,500	1	0.04	36,500	0.03	23,061	1:1	23,061
8	37,000	1	0.04	37,000	0.03	23,333	1:1	23,333
9	37,500	3	0.13	1,12,500	0.10	23,605	1:1	70,815
10	38,500	2	0.09	77,000	0.07	24,150	1:1	48,300
31	1,00,500	2	0.09	2,01,000	0.17	57,904	1:1	1,15,808
32	1,17,000	2	0.09	2,34,000	0.20	66,888	1:1	1,33,776
33	1,20,000	1	0.04	1,20,000	0.10	68,521	1:1	68,521
34	1,50,000	3	0.13	4,50,000	0.39	84,854	1:1	2,54,562
35	1,60,000	1	0.04	1,60,000	0.14	90,298	1:1	90,298
36	1,65,000	1	0.04	1,65,000	0.14	93,020	1:1	93,020
37	1,67,500	4	0.17	6,70,000	0.58	94,381	1:1	3,77,524
38	1,68,500	1	0.04	1,68,500	0.15	94,926	1:1	94,926
39	1,99,500	1	0.04	1,99,500	0.17	1,11,803	1:1	1,11,803
40	2,50,000	1	0.04	2,50,000	0.22	1,39,297	1:1	1,39,297
51	4,50,000	1	0.04	4,50,000	0.39	2,48,183	1:1	2,48,183
52	5,00,000	1	0.04	5,00,000	0.43	2,75,404	1:1	2,75,404
53	6,66,500	2	0.09	13,33,000	1.16	3,66,052	1:1	7,32,104
54	6,67,000	1	0.04	6,67,000	0.58	3,66,324	1:1	3,66,324
55	7,06,500	1	0.04	7,06,500	0.61	3,87,829	1:1	3,87,829
56	9,60,000	1	0.04	9,60,000	0.83	5,25,842	1:1	5,25,842
57	13,33,000	1	0.04	13,33,000	1.16	7,28,915	1:1	7,28,915
58	15,00,000	1	0.04	15,00,000	1.30	8,19,835	1:1	8,19,835
59	25,00,000	1	0.04	25,00,000	2.17	13,64,265	1:1	13,64,265
60	33,33,500	1	0.04	33,33,500	2.89	18,18,048	1:1	18,18,048
61	1,80,00,000	1	0.04	1,80,00,000	15.61	98,02,938	1:1	98,02,938
	Total	2,305	100.00	11,52,99,500	100.00			7,01,23,176

D. Allotment to Eligible Employees (after rejections) (including ASBA Applications)

The Basis of Allotment to the Eligible Employees, who have bid at the Offer Price of ₹30 per Equity Share or above (a discount of ₹2 per Equity Share was offered to Eligible Employees bidding under Employee Reservation Portion), was finalized in consultation with the NSE. This category has been subscribed to the extent of 0.51 times on an overall basis. The total number of Equity Shares Allotted in this category is 9,67,500 Equity Shares to 573 successful Eligible Employees. The category-wise details of the Basis of Allotment are as under:

Eligible Employees up to ₹ 0.50 million

	Eligible Employees up to < 0.30 million								
Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted	
1	500	332	57.94	1,66,000	17.16	500	1:1	1,66,000	
2	1,000	86	15.01	86,000	8.89	1000	1:1	86,000	
3	1,500	28	4.89	42,000	4.34	1500	1:1	42,000	
4	2,000	23	4.01	46,000	4.75	2000	1:1	46,000	
5	2,500	10	1.75	25,000	2.58	2500	1:1	25,000	
6	3,000	8	1.40	24,000	2.48	3000	1:1	24,000	
7	3,500	15	2.62	52,500	5.43	3500	1:1	52,500	
8	4,000	6	1.05	24,000	2.48	4000	1:1	24,000	
9	4,500	3	0.52	13,500	1.40	4500	1:1	13,500	
10	5,000	5	0.87	25,000	2.58	5000	1:1	25,000	
11	5,500	8	1.40	44,000	4.55	5500	1:1	44,000	
12	6,500	17	2.97	1,10,500	11.42	6500	1:1	1,10,500	
13	7,000	10	1.75	70,000	7.24	7000	1:1	70,000	
14	7,500	9	1.57	67,500	6.98	7500	1:1	67,500	
15	8,000	1	0.17	8,000	0.83	8000	1:1	8,000	
16	9,500	1	0.17	9,500	0.98	9500	1:1	9,500	
17	10,000	3	0.52	30,000	3.10	10000	1:1	30,000	
18	10,500	1	0.17	10,500	1.09	10500	1:1	10,500	
19	11,000	1	0.17	11,000	1.14	11000	1:1	11,000	
20	15,000	1	0.17	15,000	1.55	15000	1:1	15,000	
21	21 17,500 5 0.87		0.87	87,500	9.04	17500	1:1	87,500	
	Total	573	100.00	9,67,500	100.00			9,67,500	

Unsubscribed portion of 9,32,500 Equity Shares spilled over to QIBs, NIB and Retail Categories in the ratio of 75:15:10.

E. Allotment to QIBs (after rejections)

Allotment to QIBs, who Bid at the Offer Price of ₹30 per Equity Share or above, has been done on a proportionate basis in consultation with the NSE. This category has been subscribed to the extent of 3.50 times (including spillover from Eligible Employee category) of the Net QIB Portion. As per the SEBI ICDR Regulations, Mutual Funds were allotted 5% of the Equity Shares of the Net QIB Portion available, i.e., 1,05,39,458 Equity Shares (including spillover of 34,969 Equity Shares from Eligible Employee category) and other QIBs and unsatisfied demand of Mutual Funds were allotted the remaining available Equity Shares i.e., 20,02,49,696 Equity Shares (including spillover of 6,64,406 Equity Shares from Eligible Employee category) on a proportionate basis. The total number of Equity Shares allotted in the Net QIB Portion is 21,07,89,154 Equity Shares, which were allotted to 35 successful QIB Bidders. The category-wise details of the Basis of Allotment are as under:

Successiul QID Diu	cessial Qib bladers. The category-wise details of the basis of Allottherit are as under.										
CATEGORY	FIS/BANKS	MF's	IC's	NBFC's	AIF	FII/FPC	VC's	TOTAL			
QIB	36,69,160	2,40,12,593	50,72,459	32,56,384	28,43,609	17,19,34,949	-	21,07,89,154			

F. Allotment to Anchor Investors (after rejections)

Our Company, in consultation with the BRLMs, has allocated 31,51,34,668 Equity Shares to 33 Anchor Investors (through 52 Anchor Investor Application Forms) (including 8 domestic Mutual Funds through 26 schemes) at the Anchor Investor Offer Price of ₹30 per Equity Share in accordance with the SEBI ICDR Regulations. This represents 60% of the OIB Portion

Category	FI'S/BANK's	MF's	IC's	NBFC's	AIF	FII/FPC	OTHERS	Total
Anchor	-	11.84.03.500	4.58.03.516	-	-	15.09.27.652	-	31.51.34.668

The IPO Committee of our Company at its meeting held on November 9, 2024 has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange, being NSE and has allotted the Equity Shares to various successful applicants. The Allotment Advice-cum-Unblocking Intimations and/ or notices have been dispatched to the addresses of the investors as registered with the depositories. Further, the instructions to the SCSBs for unblocking of funds, transfers to the Public Offer Account have been issued on November 8, 2024 and payment to non-Syndicate brokers have been issued on November 9, 2024. In case the same is not received within ten days, investors may contact the Registrar to the Offer at the address given below. The Equity Shares Allotted to the successful Allottees have been uploaded on November 11, 2024 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. Our Company has filed the listing application with the NSE and BSE on November 11, 2024. Our Company has received the listing and trading approval from BSE and NSE and the trading will commence on November 12, 2024.

Note: All capitalised terms used and not specifically defined herein shall have the same meaning as ascribed to them in the Prospectus

INVESTORS PLEASE NOTE

$The \ details \ of the \ Allot ment \ made \ will \ be \ hosted \ on \ the \ website \ of the \ Registrar \ to \ the \ Offer, Link \ In time \ In dia \ Private \ Limited \ at: \ www.link in time.co. in$

All future correspondence in this regard may kindly be addressed to the Registrar to the Offer quoting full name of the first/ sole Bidder, Bid cum Application Form number, Bidder DP ID, Client ID, PAN, date of submission of Bid cum Application Form, address of the Bidder, number of Equity Shares applied for, the name and address of the Designated Intermediary where the Bid cum Application Form was submitted by the Bidder and a copy of the Acknowledgment Slip received from the Designated Intermediary at the address given below:



LINK INTIME INDIA PRIVATE LIMITED

C-101, 1st Floor, 247 Park, L.B.S. Marg, Vikhroli West, Mumbai 400 083 Maharashtra, India

Tel: +91 810 811 4949; E-mail: sagility.ipo@linkintime.co.in; Investor grievance e-mail: sagility.ipo@linkintime.co.in

Website: www.linkintime.co.in; Contact person: Shanti Gopalkrishnan; SEBI Registration No.: INR000004058

For **Sagility India Limited**On behalf of the Board of Directors

Place : Bengaluru

SatishKumar Sakharayapattana Seetharamaiah Company Secretary & Compliance Officer

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF SAGILITY INDIA LIMITED.

SAGILITY INDIA LIMITED has filed a Prospectus dated November 7, 2024 with the RoC. The Prospectus is available on the website of SEBI at www.sebi.gov.in, on the websites of the Stock Exchanges, i.e. BSE and NSE, at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.sagilityhealth.com and the websites of the Book Running Lead Managers ("BRLMs"), i.e. ICICI Securities Limited at www.icicisecurities.com, IIFL Capital Services Limited (formerly known as IIFL Securities Limited) at www.iflcap.com, Jefferies India Private Limited at www.jefferies.com and J.P. Morgan India Private Limited at www.jpmipl.com. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section titled "Risk Factors" beginning on page 40 of the Prospectus.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act"), or any state law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) under Section 4(a) of the U.S. Securities Act, and (ii) outside the United States in "offshore transactions" as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.

CONCEP